-- Company enters multi-year agreement with Colombia-based Procaps to conduct 
advanced manufacturing in Latin America 

-- Spectrum Therapeutics receives new licences, certifications, and sales in 
international jurisdictions to advance Canopy Growth's global leadership 
position and build new revenue markets 

-- Company Now Licensed for over 35 million Square Feet of Production across 
Europe, Africa and South America 

Canopy Growth Corporation ("Canopy Growth" or the "Company") 
(TSX:WEED)(NYSE:CGC) is pleased to highlight recent developments that are 
fueling its international progress in emerging medical cannabis and CBD 
markets. The Company's global three-prong strategy includes a focus on building 
best-in-class global GMP (Good Manufacturing Practices) infrastructure, 
advancing clinical research programs and best-in-class education and sales 
programs through its Spectrum Therapeutics medical division, and launching CBD 
products where regulatory environments allow. Recent highlights include:

Photo - 
https://mma.prnewswire.com/media/923519/Canopy_Growth_Corporation_Canopy_Growth_provides_update_on_inter.jpg 
 
Logo - 
https://mma.prnewswire.com/media/923525/Canopy_Growth_Corporation_Canopy_Growth_provides_update_on_inter.jpg


Latin America: 

Furthering access to these new markets, Canopy Growth has entered into a 
multi-year agreement with Procaps S.A.S ("Procaps"), a global company based in 
Colombia. Procaps develops, manufactures, and markets over-the-counter 
medications and nutritional supplements for a number of international 
pharmaceutical companies. Procaps exports to more than 50 international 
markets, including highly regulated jurisdictions such as the United States, 
where they are GMP certified by the US Food and Drug Administration ("US-FDA"). 
Through the agreement, Canopy Growth will leverage Procaps' industry-leading 
formulation and encapsulation capacity, which is especially critical in serving 
Latin American markets where there is a strong regulatory preference for 
oil-based products, including softgels. The agreement covers a number of 
different product formats.

In Colombia, Canopy Growth is licensed to produce over 13.6 million sq. ft. of 
THC or CBD dominant cannabis, making its Neiva license one of the largest in 
the world and positioning the Company to meet the emerging regional demand for 
medical cannabis and CBD products. While only a portion of the cultivation area 
is in use, the Company will scale operations as market demand dictates. The 
Company has also completed compassionate sales of Canadian-produced Spectrum 
Therapeutics products to both Chilean and Brazilian patients, validating the 
potential of serving patients through an import model while its Latin America 
operations scale and regional regulations advance to support greater market 
access.

Asia-Pacific:

In Australia, Spectrum Therapeutics received its first shipment of medical 
cannabis oil in April 2019 and shortly thereafter began sales to medical 
cannabis patients in May 2019. The medical market is expanding in Australia as 
regulations mature and patients have greater access to medical cannabis. 
Country-wide patient registrations have increased tenfold over the last year to 
more than 1,300 today. Spectrum Therapeutics intends to support Australian 
patients through imports until its domestic facilities are fully operational. 
Construction of its Victoria-based greenhouse and post-production facility is 
currently underway. 

Europe: 

In Denmark, Spectrum Therapeutics received the necessary licensing from the 
Danish Medicines Agency for its Odense facility, allowing the Company to grow, 
harvest, export and sell medical cannabis in dried flower form. To its 
knowledge, Spectrum Therapeutics is the first Canadian company to receive a 
federal production licence in Denmark. The facility, certified in both Good 
Agricultural and Collection Practices (GACP) as well as GMP designations, is 
the backbone of the Company's regional supply chain and will support the 
growing demand for Spectrum Therapeutics products across Europe. Additionally, 
following its acquisition of a licence to grow and produce cannabis in Spain, 
the Company is actively developing plans for its second site in Europe.

The Company also continues to integrate the recent strategic acquisitions of 
German-based Storz & Bickel, a global leader in medical device and vaporizer 
technology, German-based C3 Cannabinoid Compound Company, a leading European 
producer of Dronabinol, and UK-based ThisWorks. Integration of these global 
leaders into the Canopy product offering and global sales structure will 
increase revenues, accelerate intellectual property development, and further 
advance and expand clinical research.

Africa:

In Lesotho, Spectrum Therapeutics has been granted a medical production licence 
covering two facilities in the country, including 21 million sq. ft. of outdoor 
grow space and 322,000 sq. ft. of indoor, outdoor and greenhouse space 
combined, respectively, where CBD dominant and CBD-THC balanced varieties can 
be cultivated. With these licensed areas, Spectrum Therapeutics to its 
knowledge now owns one of the largest legal outdoor CBD cultivation sites on 
the continent of Africa, some of which is currently operational.

Spectrum Therapeutics has also acquired 12 hectares of land located in the 
Atlantis Economic Zone in the city of Cape Town in order to establish licensed 
production operations in South Africa. The Company has submitted the necessary 
applications for a cultivation and post-harvest processing facility licence, 
which will complement its current production capabilities in Lesotho.

For years, Canopy Growth has taken the long-view, leveraging its substantial 
cash position to lay the foundation for a global, revenue-generating network. 
These latest milestones, from world-wide land acquisitions and partnerships, 
facility developments, licence accreditations, crop cultivation - and sales - 
validate the Company's efforts and strategic investments, strengthening its 
position as the global leader, poised to capitalize on emerging markets. 

Wondering about North America? Stay tuned for further updates in the coming 
days.  

Here's to Future Growth (on the global stage).

https://c212.net/c/link/?t=0&l=en&o=2498935-1&h=4205563227&u=https%3A%2F%2Fwww.facebook.com%2Fcanopygrowth%2F&a=https%3A%2F%2Fwww.facebook.com%2Fcanopygrowth%2F


https://c212.net/c/link/?t=0&l=en&o=2498935-1&h=1427250569&u=https%3A%2F%2Ftwitter.com%2FCanopyGrowth&a=https%3A%2F%2Ftwitter.com%2FCanopyGrowth 


About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, 
hemp and cannabis device company, offering distinct brands and curated cannabis 
varieties in dried, oil and Softgel capsule forms, as well as medical devices 
through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product 
and process innovation to market execution, Canopy Growth is driven by a 
passion for leadership and a commitment to building a world-class cannabis 
company one product, site and country at a time. Canopy Growth has operations 
in over a dozen countries across five continents.

Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to 
educating healthcare practitioners, conducting robust clinical research, and 
furthering the public's understanding of cannabis, and has devoted millions of 
dollars toward cutting edge, commercializable research and IP development. 
Spectrum Therapeutics sells a range of full-spectrum products using its 
colour-coded classification Spectrum system as well as single cannabinoid 
Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning 
Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand 
which has built a large and loyal following by focusing on quality products and 
meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York 
Stock Exchange to our continued international expansion, pride in advancing 
shareholder value through leadership is engrained in all we do at Canopy 
Growth. Canopy Growth has established partnerships with leading sector names 
including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA 
Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation 
Brands, to name but a few. Canopy Growth operates eleven licensed cannabis 
production sites with over 4.7 million square feet of production capacity, 
including over one million square feet of GMP certified production space. For 
more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of 
the United States Private Securities Litigation Reform Act of 1995 and 
"forward-looking information" within the meaning of applicable Canadian 
securities legislation. Often, but not always, forward-looking statements and 
information can be identified by the use of words such as "plans", "expects" or 
"does not expect", "is expected", "estimates", "intends", "anticipates" or 
"does not anticipate", or "believes", or variations of such words and phrases 
or state that certain actions, events or results "may", "could", "would", 
"might" or "will" be taken, occur or be achieved. Forward-looking statements or 
information involve known and unknown risks, uncertainties and other factors 
which may cause the actual results, performance or achievements of Canopy 
Growth or its subsidiaries to be materially different from any future results, 
performance or achievements expressed or implied by the forward-looking 
statements or information contained in this news release. Examples of such 
statements include statements with respect to international operations and 
expansion. Risks, uncertainties and other factors involved with forward-looking 
information could cause actual events, results, performance, prospects and 
opportunities to differ materially from those expressed or implied by such 
forward-looking information, including the Company's ability to satisfy 
provincial sales contracts or provinces purchasing all cannabis allocated to 
them, and such risks contained in the Company's annual information form dated 
June 27, 2018 and filed with Canadian securities regulators available on the 
Company's issuer profile on SEDAR at www.sedar.com. Although the Company 
believes that the assumptions and factors used in preparing the forward-looking 
information or forward-looking statements in this news release are reasonable, 
undue reliance should not be placed on such information and no assurance can be 
given that such events will occur in the disclosed time frames or at all. The 
forward-looking information and forward-looking statements included in this 
news release are made as of the date of this news release and the Company does 
not undertake an obligation to publicly update such forward-looking information 
or forward-looking information to reflect new information, subsequent events or 
otherwise unless required by applicable securities laws.

For further information: 
Caitlin O'Hara, Media Relations, Caitlin.Ohara@canopygrowth.com, 613-291-3239; 
Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 
ext. 122 

SOURCE  Canopy Growth Corporation